Abstract: The invention relates to adenine receptor ligands useful for treating, alleviating and/or preventing diseases and disorders related to adenine receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The invention is further directed to the use of these compounds, alone or in combination with other therapeutic agents, for the alleviating, preventing and/or treating diseases and disorders, especially the use as antinociceptive or neuroprotective drugs.

Abstract: Disclosed is a device for generating a uniform magnetic field and to an optimization method for magnetic fields in a sample space, the method providing specifications for producing such a device. The device comprises at least one field coil for generating the magnetic field and the turns of the field coil are continuously wound around the sample space and the turn diameter of the field coil changes continuously at least in a portion of the field coil along the longitudinal axis of the sample space. To this end, the correction of non-uniformities in the magnetic field caused by the finite length of the field coil is distributed over the entire field coil. In this way, the device can be implemented more easily and precisely than with the correction coils used according to the prior art for correcting non-uniformities.

Abstract: The invention relates to a process for isolating neural cells using tenascin-R compounds, tenascin-R fragments and tenascin-R fusion proteins that are particularly suitable for such process, the recombinant preparation of such tenascin-R compounds, and a kit for performing this process, and the use of the process for preparing highly pure neural cell populations. The invention further relates to antibodies suitable for the detection and isolation of tenascin-R compounds.

Abstract: The invention relates to antibodies for use for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical and diagnostical compositions comprising such antibodies. The invention also relates to a method for identifying and/or scoring prostate carcinomas. Furthermore, the invention relates to the use of at least one siRNA (“short interfering RNA”) and/or at least one anti-LSD1 antibody for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal or for the manufacture of a medicament for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal. The invention also relates to a pharmaceutical composition for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one siRNA and/or at least one anti-LSD1 antibody suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal.

Abstract: The present invention relates to novel P2Y12 receptor antagonists useful for treating, alleviating and/or preventing diseases and disorders related to P2Y12 receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The present invention is further directed to the use of these compounds, alone or in combination with other therapeutic agents, for the alleviation, prevention and/or treatment of diseases and disorders, especially the use as antithrombotic agents for inhibiting platelet aggregation.

Abstract: The present invention relates to the cloning, sequencing and analysing of a gene cluster encoding a modular polyketide synthase enzyme involved in the biosynthesis of the antitumor compound pederin. This novel cluster represents the first example of genes from an unculturable symbiont encoding the biosynthesis of a drug candidate.

Abstract: The invention relates to a method for the identification of atypical p-ANCA, kits suitable for the same and application of said method to the diagnosis of chronic inflammatory intestinal diseases and autoimmune liver diseases.

Abstract: The present invention relates generally to the field of Hepatitis B variants exhibiting a reduced sensitivity to nucleoside analogues both in vivo and in vitro. More in particular, reverse transcriptase mutant rt I233V is provided. Present invention provides assays and methods for detecting such variant, which assays are useful in monitoring anti-viral therapeutic regimes and adjusting patient therapy. A diagnostic kit for detecting the presence of an HBV variant in a biological sample has also been described. Finally, the use of a farmaceutical composition to cure a subject suffering from a HBV infection, which HBV is resistant to lamuvidine and/or adefovir has been provided, which farmaceutical composition comprises the nucleoside analogue tenofovir.